Xtl Biopharmaceuticals (XTLB) Cash from Financing Activities (2010 - 2015)
Xtl Biopharmaceuticals (XTLB) posted quarterly Cash from Financing Activities of $20000.0 for Q4 2015, down 99.44% on a QoQ basis from $3.6 million in Q2 2015.
Xtl Biopharmaceuticals (XTLB) Cash from Financing Activities (2010 - 2015) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Cash from Financing Activities for 6 consecutive years, with $20000.0 the latest figure, recorded in Q4 2015.
- Quarterly Cash from Financing Activities changed N/A year-over-year to $20000.0 in Q4 2015, while the trailing twelve-month figure through Dec 2015 was $3.6 million (up 1058.25% YoY) and the FY2025 annual result came in at $208000.0, down 85.63% from the prior year.
- Cash from Financing Activities slipped to $20000.0 in Q4 2015 per XTLB's latest filing, from $3.6 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for XTLB reached as high as $3.8 million in Q1 2012 and fell as low as -$15000.0 in Q2 2011.
- A 5-year average of $639500.0 and a median of $74000.0 in 2012 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2011 — Cash from Financing Activities sank 100.48% — and 2012, when it surged 5742.86%.
- Year by year, Cash from Financing Activities stood at -$7000.0 in 2011, then surged by 1271.43% to $82000.0 in 2012, then jumped by 109.76% to $172000.0 in 2013, then slumped by 92.44% to $13000.0 in 2014, then soared by 53.85% to $20000.0 in 2015.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $20000.0, $3.6 million, and $13000.0 for Q4 2015, Q2 2015, and Q3 2014 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 53,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 68.63 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 238.74 Mn |
| 10 | Xtl Biopharmaceuticals | 2.58 Bn | 2.58 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 20,000.00 |
| Dec 31, 2015 | 20,000.00 |
| Jun 30, 2015 | 3.56 Mn |
| Jun 30, 2015 | 3.56 Mn |
| Sep 30, 2014 | 13,000.00 |
| Sep 30, 2014 | 13,000.00 |
| Jun 30, 2014 | 66,000.00 |
| Jun 30, 2014 | 66,000.00 |
| Mar 31, 2014 | 230,000.00 |
| Mar 31, 2014 | 230,000.00 |
| Dec 31, 2013 | 172,000.00 |
| Dec 31, 2013 | 172,000.00 |
| Sep 30, 2013 | 127,000.00 |
| Sep 30, 2013 | 127,000.00 |
| Jun 30, 2013 | 9,000.00 |
| Jun 30, 2013 | 9,000.00 |
| Mar 31, 2013 | 9,000.00 |
| Mar 31, 2013 | 9,000.00 |
| Dec 31, 2012 | 82,000.00 |
| Dec 31, 2012 | 82,000.00 |